Just a moment, the page is loading...

GSK-103477




Study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus
Rotavirus Vaccine
103477
NCT00169455
Infections, Rotavirus
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.
January 2014